121 related articles for article (PubMed ID: 37427650)
41. Early dynamic imaging in
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; Warwitz B; Scarpa L; Roig LG; Kendler D; von Guggenberg E; Bektic J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):765-775. PubMed ID: 27900519
[TBL] [Abstract][Full Text] [Related]
42.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
43. Detection Efficacy of Hybrid
Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
[TBL] [Abstract][Full Text] [Related]
44. A Multicenter Prospective Clinical Trial of
McCarthy M; Francis R; Tang C; Watts J; Campbell A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
[TBL] [Abstract][Full Text] [Related]
45. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
46. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
[TBL] [Abstract][Full Text] [Related]
47. Comparison of Dual-Tracer PET and CT Features to Conventional Risk Categories in Assessing Response to
Adnan A; Basu S
J Nucl Med Technol; 2020 Jun; 48(2):148-153. PubMed ID: 32111660
[TBL] [Abstract][Full Text] [Related]
48. Predictive factors of tumor sink effect: Insights from
Tuncel M; Telli T; Tuncalı MÇ; Karabulut E
Ann Nucl Med; 2021 May; 35(5):529-539. PubMed ID: 33586096
[TBL] [Abstract][Full Text] [Related]
49. Schwannoma Showing Avid Uptake on 68Ga-PSMA-HBED-CC PET/CT.
Kanthan GL; Izard MA; Emmett L; Hsiao E; Schembri GP
Clin Nucl Med; 2016 Sep; 41(9):703-4. PubMed ID: 27405039
[TBL] [Abstract][Full Text] [Related]
50. Diffuse bone metastases on (68)Ga-PSMA PET-CT in a patient with prostate cancer and normal bone scan.
Lavalaye J; Kaldeway P; van Melick HH
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1563-4. PubMed ID: 27121692
[TBL] [Abstract][Full Text] [Related]
51. Comparison of 68Ga-PSMA-I/T PET-CT and Multiparametric MRI for Locoregional Staging of Prostate Cancer Patients: A Pilot Study.
Çelen S; Gültekin A; Özlülerden Y; Mete A; Sağtaş E; Ufuk F; Yüksel D; Yağcı B; Zümrütbaş AE
Urol Int; 2020; 104(9-10):684-691. PubMed ID: 32750695
[TBL] [Abstract][Full Text] [Related]
52. Retrospective correlation of
Onal C; Torun N; Oymak E; Guler OC; Reyhan M; Yapar AF
Ann Nucl Med; 2020 Jun; 34(6):388-396. PubMed ID: 32221791
[TBL] [Abstract][Full Text] [Related]
53. Whole-Body Integrated [
Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
[TBL] [Abstract][Full Text] [Related]
54. Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer.
Afaq A; Bomanji J
Br Med Bull; 2018 Dec; 128(1):37-48. PubMed ID: 30272121
[TBL] [Abstract][Full Text] [Related]
55. Diagnostic performance of
Afshar-Oromieh A; Holland-Letz T; Giesel FL; Kratochwil C; Mier W; Haufe S; Debus N; Eder M; Eisenhut M; Schäfer M; Neels O; Hohenfellner M; Kopka K; Kauczor HU; Debus J; Haberkorn U
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1258-1268. PubMed ID: 28497198
[TBL] [Abstract][Full Text] [Related]
56. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
57. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
[TBL] [Abstract][Full Text] [Related]
58. Detection of metastases in newly diagnosed prostate cancer by using 68Ga-PSMA PET/CT and its relationship with modified D'Amico risk classification.
Simsek DH; Sanli Y; Engin MN; Erdem S; Sanli O
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1639-1649. PubMed ID: 32789600
[TBL] [Abstract][Full Text] [Related]
59. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN
Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428
[TBL] [Abstract][Full Text] [Related]
60. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
Uprimny C; Kroiss AS; Fritz J; Decristoforo C; Kendler D; von Guggenberg E; Nilica B; Maffey-Steffan J; di Santo G; Bektic J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1647-1655. PubMed ID: 28589253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]